Amgen Reports Real-World Evidence for Repatha in LDL Cholesterol Reduction

Amgen today presented real-world evidence for Repatha (evolocumab) in patients with high cardiovascular risk treated in clinical practice. The data showed that Repatha achieved significant LDL cholesterol reductions of approximately 55% in real-world patients, consistent with clinical trial results. Adherence rates were high, with over 80% of patients remaining on therapy at 12 months.